An all-star team of patent litigators could not persuade the U.S. Supreme Court to revive a $1.2 billion judgment over a cancer treatment patent.

The justices denied cert in Juno Therapeutics v. Kite Pharma, leaving in place a decision of the U.S. Court of Appeals for the Federal Circuit that invalidated Juno’s and Sloan Kettering Institute for Cancer Research’s 7,446,190 patent.